New Delhi: A day after the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) recommended granting permission for emergency use of the Oxford vaccine, the expert panel on Saturday gave similar direction for the indigenously developed coronavirus vaccine Covaxin with certain conditions.
Bharat Biotech, which has developed Covaxin in collaboration with Indian Council of Medical Research (ICMR), had applied to the Drugs Controller General Of India (DCGI) seeking emergency use authorisation (EUA) for its Covaxin on December 7.
The expert committee, which had asked for further data on its phase 3 trials, again deliberated on emergency use application of the Hyderabad-based pharma company after they submitted additional data, facts and analysis, The Indian Express reported.
Also Read: Govt Panel Okays Oxford Vaccine In India, DCGI To Take Final Call On Rollout
Also Read: After Pfizer & SII, Bharat Biotech Too Seeks Emergency Use Approval For Covaxin
Also Read: Covaxin Capable Of Dealing With New COVID Strains, Says Bharat Biotech Chairman
